This study presents a new experimental gene-editing strategy designed to selectively eliminate cancer cells by leveraging RNA-guided CRISPR technology.

Researchers focused on CRISPR-Cas12a2, an RNA-guided nuclease capable of trans-nucleolytic activity, and reprogrammed it to detect cancer-specific RNA transcripts.Many cancers are driven by genetic mutations in key tumor suppressor genes such as TP53, which is frequently altered in nearly 40–50% of cases.

However, these mutations have been difficult to target therapeutically because the resulting proteins often lack suitable binding pockets for traditional drugs, and restoring their normal function has proven challenging.In this approach, the engineered Cas12a2 system senses specific RNA signatures associated with cancer cells.Once activated by these transcripts, the nuclease triggers widespread chromatin degradation, a process described as “chromatin shredding.” This leads to extensive DNA damage, activation of cellular stress responses, and ultimately cell death.

The mechanism is distinct from conventional CRISPR gene editing, as it relies on RNA detection rather than direct DNA sequence targeting, enabling a form of molecular sensing that can distinguish cancerous from healthy cells based on transcriptomic profiles.

The authors suggest that this RNA-triggered chromatin destruction could represent a new class of precision oncology tools aimed at “undruggable” mutations.

By coupling RNA recognition with destructive nuclease activity, the system may allow for highly selective targeting of tumor cells while sparing normal tissue.

Although the findings are currently presented in an unedited manuscript form and require further validation, the study highlights a potentially transformative direction in cancer therapy that integrates RNA sensing, genome instability induction, and programmable nucleases for selective cell elimination.